Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ChemAxon Provides Chemistry Informatics Platform for the European Lead Factory

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
ChemAxon will provide the core tools to support the pan European initiative.

ChemAxon and the European Lead Factory have announced that ChemAxon will provide the core tools and leads the development of the informatics platform to support the pan European initiative.

ChemAxon will be building a portal to support the crowd-sourcing initiative using its core JChem Base and Marvin components.

The scientific decision process involved in selecting the right proposals from those submitted will be supported by ChemAxon’s Discovery Toolkit, including various fingerprints and physico-chemical property predictors.

The portal will also offer a way for submitters to keep track of their submission’s status and for the consortium’s selection committee to score and analyze submitted proposals.

The Innovative Medicines Initiative (IMI), the world’s largest public-private initiative in the field of pharmaceutical research aims to create a new and unique collaboration of public and private sector.

The research program of up to EUR196 million and named the European Lead Factory, involving small and medium-sized enterprises (SMEs), academic institutions and large pharmaceutical companies, aims to improve the competitiveness of the European pharmaceutical industry, accelerate the drug development process, and strives to develop safer, more effective drugs.

The European Lead Factory was launched by an international consortium of 30 partners, with the only Hungarian participant being ChemAxon Ltd. This partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates unprecedented opportunities for the discovery of new medicines through access to a collection of small molecules contributed by pharmaceutical companies, and a newly synthesized compound collection built by the SMEs and academic institutions.

As a result of this partnership, the new compound library consisting of up to half a million compounds will be accessible to all project partners and to public organizations.

Screening of this compound collection will be performed within the pharmaceutical companies and by a newly established European Screening Centre, which will run state of the art facilities in Scotland and the Netherlands to handle logistics and screening of compound libraries.

If the project proves successful during its initial five year funding period, the partnership aims for a sustainable role in drug discovery in Europe.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ChemAxon Extends chemicalize.org Free Service with Predicted Data and User Customization
The new features help users understand better the chemical structure with more predicted properties and a customizable layout.
Monday, August 23, 2010
Broad Institute Acquires License to all ChemAxon Products and Deploys Across Chemical Biology Platform
License covers ChemAxon’s platform, discovery toolkits and desktop applications for institute-wide use.
Friday, August 20, 2010
ChemAxon Announces new CEO and Head of R&D
Company increases its focus on business development and market position with new appointments.
Tuesday, May 13, 2008
Migrating Chemical Information to New Architectures
New ChemAxon whitepaper discusses the drivers behind the increasing number of pharma and biotech companies moving from traditional proprietary chemical information systems to modern alternatives.
Monday, January 29, 2007
Scientific News
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!